Health Care Cost Analysis in a Population-based Inception Cohort of Inflammatory Bowel Disease Patients in the First Year of Diagnosis
Autor: | William Connell, O Niewiadomski, Paul Dabkowski, Jarrad Wilson, Christopher Hair, Mark Tacey, Emily Prewett, Benjamin Allen, John McNeill, Paul V. Desmond, Damian Dowling, Sina Alexander, Ross Knight, Sally Bell, Corrie Studd |
---|---|
Rok vydání: | 2015 |
Předmět: |
Adult
Male medicine.medical_specialty Adolescent Victoria medicine.medical_treatment Population Anti-Inflammatory Agents Inflammatory bowel disease Young Adult Gastrointestinal Agents Interquartile range Internal medicine Health care medicine Ambulatory Care Humans Prospective Studies Registries education Prospective cohort study Child Aged Aged 80 and over Crohn's disease education.field_of_study business.industry Gastroenterology General Medicine Health Care Costs Middle Aged medicine.disease Inflammatory Bowel Diseases Combined Modality Therapy Cohort Physical therapy Female business Watchful waiting Immunosuppressive Agents Follow-Up Studies |
Zdroj: | Journal of Crohn'scolitis. 9(11) |
ISSN: | 1876-4479 |
Popis: | Background: There are limited prospective population-based data on the health care cost of IBD in the post-biologicals era. A prospective registry that included all incident cases of inflammatory bowel disease [IBD] was established to study disease progress and health cost. Aim: To prospectively assess health care costs in the first year of diagnosis among a well-characterised cohort of newly diagnosed IBD patients. Method: Incident cases of IBD were prospectively identified in 2007–2008 and 2010–2013 from multiple health care providers, and enrolled into the population-based registry. Health care resource utilisation for each patient was collected through active surveillance of case notes and investigations including specialist visits, diagnostic tests, medications, medical hospitalisation, and surgery. Results: Off 276 incident cases of IBD, 252 [91%] were recruited to the registry, and health care cost was calculated for 242 (146 Crohn’s disease [CD] and 96 ulcerative colitis [UC] patients). The median cost in CD was higher at A$5905 per patient (interquartile range [IQR]: A$1571-$91,324) than in UC at A$4752 [IQR: A$1488-A$58,072]. In CD, outpatient resources made up 55% of all cost, with medications accounting for 32% of total cost [15% aminosalicylates, 15% biological therapy], followed by surgery [31%], and diagnostic testing [21%]. In UC, medications accounted for 39% of total cost [of which 37% was due to 5-aminosalicylates, and diagnostics 29%; outpatient cost contributed 71% to total cost. Conclusion: In the first year of diagnosis, outpatient resources account for the majority of cost in both CD and UC. Medications are the main cost driver in IBD. |
Databáze: | OpenAIRE |
Externí odkaz: |